Want to see TYRA full AI Analyst Report?
Top Page
Tyra Bioscience
(NASDAQ:TYRA)
Select Model
Select Model
Rating:53Neutral
Price Target:
$20.50
▼(-21.82% Downside)
Action:Reiterated
Date:09/16/26
The score is held back primarily by weak financial performance typical of a pre-revenue biotech—widening losses and increasing cash burn—alongside a generally bearish technical trend. Offsetting these risks are strong recent corporate developments, including encouraging Phase 2 clinical data and a large equity raise that improves funding capacity. Valuation contributes negatively due to ongoing unprofitability and no dividend support.
Positive Factors
Low Leverage and Strong Equity Base
Very low leverage and substantial equity reduce near-term solvency pressure and give Tyra flexibility to fund clinical development. This stronger balance-sheet position can support continued investment in its pipeline while limiting the constraints that high debt would impose on strategic choices.
Negative Factors
Pre-Revenue and Widening Losses
Tyra has no approved-product revenue to offset rising research and development costs, while net and operating losses continue to widen. This weak earnings profile limits internal funding capacity and leaves future value dependent on successful clinical progress and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Strong Equity Base
Very low leverage and substantial equity reduce near-term solvency pressure and give Tyra flexibility to fund clinical development. This stronger balance-sheet position can support continued investment in its pipeline while limiting the constraints that high debt would impose on strategic choices.
Read all positive factors
Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.39B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth-33.90%
CountryUS
Employees87
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding68,755,936
10 Day Avg. Volume974,250
30 Day Avg. Volume1,129,131
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.75K
Enterprise Value/Ebitda-11.88
Forecast
1Y Price Target
$47.40Price Target Upside80.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.65
Revenue Forecast (FY)N/A
Tyra Bioscience Business Overview & Revenue Model
Company Description
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fi...
How the Company Makes Money
TYRA is a clinical-stage biopharmaceutical company and does not have recurring product sales from approved drugs. Its ability to make money is therefore primarily tied to (1) raising capital through equity financings (e.g., public offerings) and p...
Tyra Bioscience Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -148.03M | -119.40M | -85.96M | -68.78M | -55.03M | -26.15M |
| Net Income | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
Balance Sheet | ||||||
| Total Assets | 383.36M | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Cash, Cash Equivalents and Short-Term Investments | 353.94M | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Total Debt | 5.58M | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Total Liabilities | 29.70M | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Stockholders Equity | 353.66M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
Cash Flow | ||||||
| Free Cash Flow | -109.90M | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Operating Cash Flow | -109.65M | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Investing Cash Flow | -82.82M | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Financing Cash Flow | 167.81M | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
Tyra Bioscience Technical Analysis
Negative
26.22
Price Trends
25.26
Negative
28.05
Negative
30.47
Negative
Market Momentum
-1.45
Positive
36.41
Neutral
20.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Negative. The current price of 26.22 is above the 20-day moving average (MA) of 22.87, above the 50-day MA of 25.26, and below the 200-day MA of 30.47, indicating a bearish trend. The MACD of -1.45 indicates Positive momentum. The RSI at 36.41 is Neutral, neither overbought nor oversold. The STOCH value of 20.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TYRA.
Tyra Bioscience Risk Analysis
Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tyra Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.96B | -6.23 | -29.99% | ― | 1495.93% | 53.66% | |
58 Neutral | $936.76M | -3.17 | -207.18% | ― | -7.27% | -48.89% | |
53 Neutral | $1.39B | -8.50 | -46.39% | ― | ― | -33.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.55B | -6.76 | -372.94% | ― | 222.65% | 35.43% | |
50 Neutral | $842.04M | -4.67 | -43.31% | ― | -83.86% | -646.52% | |
44 Neutral | $744.05M | -4.59 | -50.26% | ― | ― | 8.22% |
* Healthcare Sector Average
TYRA
Tyra Bioscience
20.39
6.76
49.60%
KURA
Kura Oncology
10.67
0.59
5.85%
SNDX
Syndax Pharmaceuticals
17.03
0.53
3.21%
VIR
Vir Biotechnology
11.52
5.47
90.41%
GLUE
Monte Rosa Therapeutics
10.17
2.46
31.91%
AVBP
ArriVent BioPharma, Inc.
16.89
-3.93
-18.88%
Tyra Bioscience Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Tyra Bioscience announces $400M equity financing offering
Positive
Sep 15, 2026
On September 14, 2026, Tyra Biosciences priced an underwritten offering of 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 additional shares at around $22 per share, targeting gross proceeds of approximately $400 million. Th...
Business Operations and StrategyProduct-Related Announcements
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data
Positive
Sep 9, 2026
On September 9, 2026, Tyra Biosciences reported initial Phase 2 data from its SURF302 trial of oral dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, showing favorable safety at 50 mg and 60 mg once-dail...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.